Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Says Vaccines Getting Back On Track, Rejects M&A

This article was originally published in The Pink Sheet Daily

Executive Summary

The company has addressed its vaccine manufacturing issues and is about to resubmit MS therapy Lemtrada to FDA; it reported a 4.7% sales increase in the first quarter, driven by growth in its diabetes and consumer health divisions and Genzyme.

Advertisement

Related Content

Emerging Markets Earnings Roundup: Sanofi (Part 10)
Emerging Markets Earnings Roundup: Sanofi (Part 10)
Preparing For Battle: PCSK9 Sponsors Stake Their Ground
Genzyme Will Appeal Lemtrada “Complete Response” After FDA Seeks More Trials

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS077153

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel